Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Non-Current Liabilities (2020 - 2024)

Kymera Therapeutics (KYMR) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $142.4 million as the latest value for Q4 2024.

  • On a quarterly basis, Total Non-Current Liabilities fell 21.22% to $142.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $142.4 million, a 21.22% decrease, with the full-year FY2024 number at $142.4 million, down 21.22% from a year prior.
  • Total Non-Current Liabilities was $142.4 million for Q4 2024 at Kymera Therapeutics, down from $180.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $203.2 million in Q4 2020 to a low of $112.7 million in Q4 2022.
  • A 5-year average of $153.5 million and a median of $149.0 million in 2023 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: decreased 29.14% in 2022, then skyrocketed 60.37% in 2023.
  • Kymera Therapeutics' Total Non-Current Liabilities stood at $203.2 million in 2020, then decreased by 28.05% to $146.2 million in 2021, then fell by 22.89% to $112.7 million in 2022, then surged by 60.37% to $180.8 million in 2023, then dropped by 21.22% to $142.4 million in 2024.
  • Per Business Quant, the three most recent readings for KYMR's Total Non-Current Liabilities are $142.4 million (Q4 2024), $180.8 million (Q4 2023), and $156.8 million (Q3 2023).